

Beat: Miscellaneous

CSL BEHRING EXPANDS TO RUSSIA TO PROVIDE GREATER ACCESS TO TREATMENT

ITS LATEST GEOGRAPHIC EXPANSION

PARIS - MOSCOW, 09.12.2015, 13:05 Time

USPA NEWS - Global biotherapeutics leader CSL Behring announced on December 8, its latest geographic expansion to provide more patients with greater access to treatment by opening operations in Russia. This is particularly significant in Russia where the healthcare system has some unmet needs for...

Global biotherapeutics leader CSL Behring announced on December 8, its latest geographic expansion to provide more patients with greater access to treatment by opening operations in Russia. This is particularly significant in Russia where the healthcare system has some unmet needs for state-of-the-art biotherapies and blood plasma products.

The annual usage of certain classes of these medicines in Russia is much lower than it should be. For example, consumption of immunoglobulins in Russia per capita is 10 to 20 times lower than in the USA and some European countries.

With operations in over 30 countries, CSL Behring focuses on developing novel, protein-based therapies for the treatment of bleeding disorders, immune deficiencies, inherited respiratory disease and hereditary angioedema, and for neurological disorders in certain markets.

CSL CEO and Managing Director Paul Perreault, who joined Russian healthcare leaders and patient advocates at the office opening on December 8, said the new office enables CSL Behring to partner more closely with the Russian Federation, healthcare providers, patient groups and the scientific community. The company currently has seven products registered in Russia.

In addition, CSL Behring is investigating opportunities to contribute to the development of the Russian pharmaceutical industry, and identify the best ways to partner with the Russian government. As an example, because the amount of human plasma that is currently collected in Russia is insufficient to meet the growing demand for protein-based medicines, Perreault said it may be possible to transfer CSL Behring's plasma collection technology to Russia, and initiate toll manufacturing in that country.

Source : CSL Behring

Ruby BIRD

<http://www.portfolio.uspa24.com/>

Yasmina BEDDOU

<http://www.yasmina-beddou.uspa24.com/>

Article online:

<https://www.uspa24.com/bericht-6682/csl-behring-expands-to-russia-to-provide-greater-access-to-treatment.html>

Editorial office and responsibility:

V.i.S.d.P. & Sect. 6 MDSiV (German Interstate Media Services Agreement): Ruby BIRD & Yasmina BEDDOU (Journalists/Directors)

Exemption from liability:

The publisher shall assume no liability for the accuracy or completeness of the published report and is merely providing space for the submission of and access to third-party content. Liability for the content of a report lies solely with the author of such report. Ruby BIRD & Yasmina BEDDOU (Journalists/Directors)

Editorial program service of General News Agency:

UPA United Press Agency LTD

483 Green Lanes

UK, London N13NV 4BS

contact (at) unitedpressagency.com

Official Federal Reg. No. 7442619